This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Updated with the latest research since the 2020 edition, this comprehensive report underscores the potential to prevent or significantly delay dementia by targeting modifiable riskfactors. The report now identifies 14 modifiable riskfactors for dementia.
Introduction:Excessive dietary salt intake is a recognized ASCVD riskfactor, and causes approximately 1.89 There is also an ongoing discussion whether dietary salt might be associated with the direct ASCVD risk. Circulation, Volume 150, Issue Suppl_1 , Page A4145926-A4145926, November 12, 2024. million deaths annually.
Education and Empowerment Educating patients about their condition and the importance of managing cardiometabolic riskfactors can empower them to take control of their health, improve healthcare outcomes, and reduce clinician burnout. This ensures clear communication and identifies areas that need further explanation.
Food and Drug Administration ( FDA ) has approved an additional indication for Wegovy ( semaglutide ) to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along with a reduced calorie diet and increased physical activity.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content